TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03572751

Intervention type: DIAGNOSTIC_TEST
Intervention: Bed-, wrist- and ECG-sensor monitoring
Description: Bed-, wrist- and ECG-sensor monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: Bed-, wrist- and ECG-sensor monitoring
Description: Bed-, wrist- and ECG-sensor monitoring
Study: NCT03451942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLOT regimen chemotherapy
Description: FLOT regimen chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT regimen chemotherapy
Description: FLOT regimen chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 gastric and imaging metastases resection
Description: After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
Study: NCT03126903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraKlear Non-Penetrating Keratoprosthesis
Description: The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
Study: NCT01056731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren and HCTZ
Description: Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
Study: NCT01407744

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02263209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioguard Group
Description: Patients randomised to receive the study investigative device will receive a Bioguard implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients randomised to receive the control device will receive a Exceed Taperlock implant
Study: NCT03189576

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood draw
Study: NCT03508739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 200mg (blinded)
Description: study day 2 for AB and study day 3 for BA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan 200mg (blinded)
Description: study day 2 for AB and study day 3 for BA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg (blinded)
Description: study day 3 for AB and study day 2 for BA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg (blinded)
Description: study day 3 for AB and study day 2 for BA
Study: NCT01703273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manual based low key group intervention (innovation)
Description: 6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized, manual based routine care
Description: 6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
Study: NCT00913575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative neuromuscular training
Description: The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: knee OA School
Description: The education group will only receive 4 sessions of the Knee OA School.
Study: NCT03467048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscopy
Description: Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords.
Study: NCT02236013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: lyophilized powder administered intravenously
Study: NCT01488500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: 24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: 24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
Study: NCT02236013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: lyophilized powder administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: lyophilized powder administered intravenously
Study: NCT01488500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: 24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
Study: NCT02477969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168(100µg)
Description: PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168(200µg)
Description: PEX168,Subcutaneous injection,once a week. continued for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 0.5mg,oral,tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 0.5mg,oral,tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: 0.5mg,oral,tid.
Study: NCT01631812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM 962
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02496065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study: NCT01907100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: triple kinase inhibitor; 200mg starting dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: backbone chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: backbone chemo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: backbone chemo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: backbone chemo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nintedanib matching placebo
Study: NCT05002283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient specific guide
Description: harvesting palatal free gingival graft using the patient specific guide
Study: NCT01315184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Line Support System
Description: Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback.
Study: NCT00991744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine
Description: Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal triple
Description: Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
Study: NCT05209542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterosalpingo-Foam Ultrasonography
Description: * Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterosalpingo-Foam Ultrasonography
Description: * Initial 3-5 ml of foam contrast is to be introduced slowly into the endometrial cavity while the flow of contrast medium in each tube is evaluated using grayscale and power Doppler imaging~* Power Doppler is very helpful to confirm the direction of the flow as well as the acceleration during injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: • Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: • Standard laparoscopic evaluation with the dye test (methylene blue staining) is to be performed 1 day after ultrasound tests with 1 day of hospitalization under general anesthesia
Study: NCT04267146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.
Study: NCT02725281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress ball
Description: The patients in this group were given stress ball into both their palms 5 minutes before ESWL. Participants were instructed to squeeze the balls twice after counting up to ten and repeat it until the end of the procedure. This ball was medium hard and has been made of high quality silicon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
Study: NCT02236013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: lyophilized powder administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: solution administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: solution administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: solution administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: solution administered intravenously
Study: NCT03549806

Intervention type: DIAGNOSTIC_TEST
Intervention: No Intervention. Test is computer algorithm.
Description: Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
Study: NCT02316314

Intervention type: PROCEDURE
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart.

Intervention type: PROCEDURE
Intervention: Cardiac magnetic resonance imaging (CMR)
Description: CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart.

Intervention type: PROCEDURE
Intervention: Exercise-stress test
Description: You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.

Intervention type: PROCEDURE
Intervention: Exercise-stress test
Description: You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.

Intervention type: PROCEDURE
Intervention: Echocardiogram (ECHO)
Description: An echocardiogram is an ultrasound of the heart done at rest.

Intervention type: PROCEDURE
Intervention: Echocardiogram (ECHO)
Description: An echocardiogram is an ultrasound of the heart done at rest.

Intervention type: PROCEDURE
Intervention: Cardiac-related blood studies
Description: The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).

Intervention type: PROCEDURE
Intervention: Cardiac-related blood studies
Description: The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
Study: NCT04170842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
Study: NCT05160090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl MR tablets 300mg
Description: In each study period, a single 300 mg dose of Bupropion will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
Study: NCT03621553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Vitamin D2 50,000 units

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic ergocalciferol 50,000 units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Citrate with Vitamin D2
Description: To meet the recommended minimum daily dietary requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Citrate with Vitamin D2
Description: To meet the recommended minimum daily dietary requirements

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium Citrate with Vitamin D2
Description: To meet the recommended minimum daily dietary requirements
Study: NCT00823589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test and clinical test
Description: Blood test and clinical test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test and clinical test
Description: Blood test and clinical test
Study: NCT02236013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: solution administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: solution administered intravenously
Study: NCT03345225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureFire Infusion System
Description: Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endhole Microcatheter
Description: A Microcatheter with a single hole at the end for a infusion.
Study: NCT02794116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sealants
Description: It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin Sealants
Description: It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
Study: NCT02922413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hemin for injection
Description: Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion
Study: NCT04609553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care including ROR
Description: Usual care which includes ROR.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care including ROR
Description: Usual care which includes ROR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care including ROR
Description: Usual care which includes ROR.
Study: NCT04005833

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
Study: NCT04609553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: 3 text messages per week and one interactive text per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: 3 text messages per week and one interactive text per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to community resources
Description: Referral to a non-profit that connects families with community resources and provides families with case management.
Study: NCT03556826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Value Learning Training
Description: For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
Study: NCT04602364

Intervention type: OTHER
Intervention: Noninterventional
Description: Not applicable; Noninterventional study
Study: NCT04018664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl solution
Description: nalbuphine solution administered at various strengths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Placebo
Study: NCT04021420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOCLOUD
Description: The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~1. an implantable ultrasound transducer,~2. a needle connection device,~3. an external radiofrequency generator, and~4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab (flat dose: 240mg, 30 minutes infusion)